Compare CleanSpark Inc (CLSK) vs Quest Diagnostics Inc (DGX) Price & Performance

CleanSpark trades at $12.18, up 5.09% today but facing bearish technical signals with 17 sell indicators versus 5 buy signals. The company reported four consecutive quarterly earnings misses, with Q2 2026 showing a loss of $0.89 per share versus expectations of -$0.47. Despite negative profitability metrics including a -146.9% net income margin, analysts maintain unanimous buy ratings with a $24.13 consensus price target, representing 98% upside potential. Recent news highlights a strategic pivot to AI data centers through a $6.6 billion, 20-year lease agreement.

The stock presents a high-risk, high-reward opportunity with strong analyst conviction contrasting weak fundamentals. The AI data center expansion offers significant long-term revenue potential but requires substantial capital investment amid current cash flow challenges. Key risks include execution of the strategic pivot, continued earnings volatility, and the need for additional financing to support growth initiatives.

Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.

The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.